GenSight Biologics Strengthens Its Management Team to Suppor

Philippe Motté as Senior VP, Regulatory and QualityMichiel Hemels as VP, Global Pricing and Market AccessPARIS--(BUSINESS WIRE)--Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for reti...

Related Keywords

Saclay , France General , France , Paris , Denmark , Copenhagen , Køavn , Utrecht , Netherlands , Massachusetts , United States , Canada , Toronto , Ontario , French , Clothilde Caillet , James Palmer , Gensight Biologics Euronext , Michiel Hemels , Guillaume Van Renterghem , Jeanene Timberlake , Gensight Biologics , Philippe Mott , Bernard Gilly , Sissel Rodahl , Postdoctoral Fellowship At Harvard Medical School , French National Academy Of Pharmacy , University Of Utrecht , Hospital Cancer Center , European School Of Management Paris , Medday Pharmaceuticals , Descartes University , Sud University , University Of Toronto , Copenhagen Business School , Philippe , Professor At University Paris , Global Pricing , Market Access , Regulatory News , Sight Biologics , Senior Vice President , Chief Executive Officer Bernard Gilly , Vice President , Gensight Biologic , Gensight Biologic Chief Executive Officer , Co Founder Bernard , Paris Descartes University , Human Biology , Postdoctoral Fellowship , Harvard Medical School , Massachusetts General Hospital Cancer Center , Pharmacien Responsable , Responsible Pharmacist , French National Academy , Visiting Professor , Celestial Consulting , Chief Regulatory , Quality Officer , Pharmaceutical Sciences , Europe Middle East , Global Market Access , Relative Effectiveness Assessment , Sight Biologic , Mitochondrial Targeting Sequence , Leber Hereditary Optic Neuropathy ,